stockrow
Saturday 7 November 2026
Export NXTC’s income statement to Excel — free account
NextCure, Inc.
NXTC Healthcare Biotechnology
- EPS
- +75.2%
- Free cash flow
- +57.2%
Quarter to June 2026, against a year earlier
5.30
0.18
+3.52%
Follow NXTC
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (195.22%) | (132.40%) | (111.23%) | (116.91%) |
+8 more TTM periods Free account |
|
| (121.60%) | (104.01%) | (85.23%) | (89.28%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(265.10%) | (196.35%) | (153.19%) | (229.45%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(6.97) | (9.54) | (17.45) | (18.29) | |
Free Cash Flow |
(36.98) | (49.98) | (49.61) | (48.94) | |
| Other line items | |||||
Cash ROIC |
(114.73%) | (88.53%) | (64.63%) | (92.77%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.87 | 0.91 | 0.89 | 0.84 | |
Depreciation/Fixed assets |
4.45 | 0.51 | 0.52 | 0.49 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(6.97) | (9.54) | (17.45) | (18.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026